Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks' gestation: a randomised trial
@article{Ainsworth2000PumactantAP, title={Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks' gestation: a randomised trial}, author={Sb Ainsworth and M. W. Beresford and D. W. A. Milligan and N Shaw and Jns Matthews and AC Fenton and M. W. Platt}, journal={The Lancet}, year={2000}, volume={355}, pages={1387-1392} }
104 Citations
Complications among premature neonates treated with beractant and poractant alfa
- MedicineIndian journal of pediatrics
- 2010
In this study, infants who received poractant had shorter duration of intubation than infants treated with beractant, without any difference in the duration of oxygen therapy or hospitalization.
Is there a Difference in Surfactant Treatment of Respiratory Distress Syndrome in Premature Neonates? A Review
- Medicine
- 2013
New surfactant administration strategies are described, complimenting new respiratory support strategies, designed to minimize invasive mechanical ventilation and decrease the frequency of chronic lung disease.
An observational study of surfactant treatment in infants of 23–30 weeks' gestation: comparison of prophylaxis and early rescue
- MedicineThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
- 2003
Not surprisingly, infants treated with prophylactic surfactant had a lower rate of RDS than the infants treated by early rescue, even though they did not need less Surfactant overall.
History of Surfactant from 1980
- MedicineNeonatology
- 2005
Comparison studies show that multiple doses may be needed if surfactant is used to treat established RDS but early or prophylactic treatment is superior for infants with gestational ages less than 30 weeks, and a meta-analysis of 5 comparative studies suggests that a dose of 200 mg/kg of poractant alfa is associated with lower mortality compared with 100 mg/ kg of beractant.
Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial
- MedicinePloS one
- 2017
Poractant alfa may be more beneficial and associated with fewer complications than bovine lipid extract surfactant and larger studies are needed to determine whether observed possible benefits translate in shorter hospital admissions, or other long term benefits and determine whether there is a difference in mortality.
Surfactant Therapy for Respiratory Distress Syndrome in Premature Neonates
- MedicineAmerican journal of respiratory medicine : drugs, devices, and other interventions
- 2002
Despite being an effective therapy for RDS, surfactant has failed to have a significant impact on the incidence of chronic lung disease in survivors and is considered a cost-effective therapy compared with other therapeutic interventions in premature infants.
One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials
- MedicinePediatrics
- 2007
Surviving infants who received lucinactant and other surfactants in the SELECT and STAR trials individually and from analysis using combined data from these 2 trials sought to determine and compare survival and pulmonary and neurodevelopmental outcomes through 1 year corrected age.
Choosing a Right Surfactant for Respiratory Distress Syndrome Treatment
- MedicineNeonatology
- 2008
Evidence from randomized controlled trials indicates that treatment with natural surfactant results in faster weaning of supplemental oxygen and mean airway pressure, decreased duration of mechanical ventilation, and decreased mortality when compared to synthetic surfactants.
Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?
- Medicine, PsychologyAdvances in therapy
- 2010
The postnatal airway inflammatory response observed in preterm infants is not altered by the instillation of either surfactant preparation, and ventilation requirements and clinical outcomes were similar between the two groups.
A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
- MedicineAmerican journal of perinatology
- 2004
Treatment with poractant alfa resulted in rapid reduction in supplemental oxygen with fewer additional doses of surfactant versus treatment with beractant in infants <35 weeks gestation with RDS, and significantly reduced mortality.
References
SHOWING 1-10 OF 26 REFERENCES
A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
- MedicinePediatrics
- 1997
Treatment with Infasurf resulted in significant improvement in several secondary outcome measures and is suggested that a more effective surfactant is a better option than Exosurf in the prevention of neonatal respiratory distress syndrome.
Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.
- MedicineArchives of disease in childhood. Fetal and neonatal edition
- 1995
The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours after start of treatment, associated with a trend towards reduced incidence of serious pulmonary and non-pulmonary complications.
A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome
- Medicine
- 1996
Although no differences were noted between Survanta- and Exosurf-treated infants regarding the primary outcome of death or chronic lung disease at 28 days of age, the significant improvement in secondary clinical outcomes suggests that SurvantA is more effective than ExosURf Neonatal in the treatment of established RDS.
TWO CONTROLLED TRIALS OF DRY ARTIFICIAL SURFACTANT: EARLY EFFECTS AND LATER OUTCOME IN BABIES WITH SURFACTANT DEFICIENCY
- MedicineThe Lancet
- 1985
A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.
- MedicineThe Journal of pediatrics
- 1993
Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestation.
- MedicineEarly human development
- 1988
Manual Ventilation with a Few Large Breaths at Birth Compromises the Therapeutic Effect of Subsequent Surfactant Replacement in Immature Lambs
- MedicinePediatric Research
- 1997
It is concluded that a few inflations with volumes that are probably harmless in other circumstances might, when forced into the surfactant-deficient lung immediately at birth, compromise the effect of subsequent Surfactant rescue treatment.
Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants.
- MedicineAmerican journal of obstetrics and gynecology
- 1993
Comparison of mortality risk: a score for very low birthweight infants
- MedicineArchives of disease in childhood. Fetal and neonatal edition
- 1997
The present score is robust, easily obtainable at admission, and permits early randomisation based on mortality risk, which quantifies mortality risk in very low birthweight infants at admission to the neonatal intensive care unit.
Comparison of surface properties and physiological effects of a synthetic and a natural surfactant in preterm rabbits.
- MedicineArchives of disease in childhood. Fetal and neonatal edition
- 1994
The natural surfactant, Curosurf, reduced the contractile force at an air-liquid interface to a greater extent than the synthetic surfactants, Exosurf, and led to a great improvement in compliance and less airway epithelial damage when given in clinical treatment doses to immature rabbits.